Getting it right the first time: recent progress in optimizing antiemetic usage

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent years have witnessed significant improvements in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), allowing patients to complete their prescribed chemotherapy regimens without compromising quality of life. This reduction in the incidence of CINV can be primarily attributed to the emergence of effective, well-tolerated antiemetic therapies, including serotonin (5-hydroxytryptamine or 5-HT3) receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and the atypical antipsychotic olanzapine. While 5-HT3 receptor antagonists are highly effective in the prevention of acute CINV, NK-1 receptor antagonists and olanzapine have demonstrated considerable activity against both acute and delayed CINV. Various combinations of these three types of agents, along with dexamethasone and dopamine receptor antagonists, are now becoming the standard of care for patients receiving moderately or highly emetogenic chemotherapy. Optimal use of these therapies requires careful assessment of the unique characteristics of each agent and currently available clinical trial data.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalSupportive Care in Cancer
Volume26
DOIs
StatePublished - Mar 1 2018

Fingerprint

Antiemetics
olanzapine
Drug Therapy
Nausea
Vomiting
Neurokinin-1 Receptor Antagonists
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Serotonin
Dopamine Antagonists
Standard of Care
Antipsychotic Agents
Quality of Life
Clinical Trials
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Getting it right the first time : recent progress in optimizing antiemetic usage. / Schwartzberg, Lee.

In: Supportive Care in Cancer, Vol. 26, 01.03.2018, p. 19-27.

Research output: Contribution to journalArticle

@article{1934a99ce8144547810c32848757f188,
title = "Getting it right the first time: recent progress in optimizing antiemetic usage",
abstract = "Recent years have witnessed significant improvements in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), allowing patients to complete their prescribed chemotherapy regimens without compromising quality of life. This reduction in the incidence of CINV can be primarily attributed to the emergence of effective, well-tolerated antiemetic therapies, including serotonin (5-hydroxytryptamine or 5-HT3) receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and the atypical antipsychotic olanzapine. While 5-HT3 receptor antagonists are highly effective in the prevention of acute CINV, NK-1 receptor antagonists and olanzapine have demonstrated considerable activity against both acute and delayed CINV. Various combinations of these three types of agents, along with dexamethasone and dopamine receptor antagonists, are now becoming the standard of care for patients receiving moderately or highly emetogenic chemotherapy. Optimal use of these therapies requires careful assessment of the unique characteristics of each agent and currently available clinical trial data.",
author = "Lee Schwartzberg",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s00520-018-4116-2",
language = "English (US)",
volume = "26",
pages = "19--27",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Getting it right the first time

T2 - recent progress in optimizing antiemetic usage

AU - Schwartzberg, Lee

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Recent years have witnessed significant improvements in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), allowing patients to complete their prescribed chemotherapy regimens without compromising quality of life. This reduction in the incidence of CINV can be primarily attributed to the emergence of effective, well-tolerated antiemetic therapies, including serotonin (5-hydroxytryptamine or 5-HT3) receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and the atypical antipsychotic olanzapine. While 5-HT3 receptor antagonists are highly effective in the prevention of acute CINV, NK-1 receptor antagonists and olanzapine have demonstrated considerable activity against both acute and delayed CINV. Various combinations of these three types of agents, along with dexamethasone and dopamine receptor antagonists, are now becoming the standard of care for patients receiving moderately or highly emetogenic chemotherapy. Optimal use of these therapies requires careful assessment of the unique characteristics of each agent and currently available clinical trial data.

AB - Recent years have witnessed significant improvements in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), allowing patients to complete their prescribed chemotherapy regimens without compromising quality of life. This reduction in the incidence of CINV can be primarily attributed to the emergence of effective, well-tolerated antiemetic therapies, including serotonin (5-hydroxytryptamine or 5-HT3) receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and the atypical antipsychotic olanzapine. While 5-HT3 receptor antagonists are highly effective in the prevention of acute CINV, NK-1 receptor antagonists and olanzapine have demonstrated considerable activity against both acute and delayed CINV. Various combinations of these three types of agents, along with dexamethasone and dopamine receptor antagonists, are now becoming the standard of care for patients receiving moderately or highly emetogenic chemotherapy. Optimal use of these therapies requires careful assessment of the unique characteristics of each agent and currently available clinical trial data.

UR - http://www.scopus.com/inward/record.url?scp=85044230142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044230142&partnerID=8YFLogxK

U2 - 10.1007/s00520-018-4116-2

DO - 10.1007/s00520-018-4116-2

M3 - Article

C2 - 29556812

AN - SCOPUS:85044230142

VL - 26

SP - 19

EP - 27

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -